
Republicans and Democrats Unite Against Pharmacy Benefit Managers
Key Takeaways
- PBMs are facing bipartisan scrutiny for their role in rising drug costs.
- States are moving to restrict PBMs from owning retail pharmacy chains.
- Critics argue the PBM market lacks true competition and transparency.
- PBM industry representatives claim they are unfairly blamed for systemic pricing issues.
Ad placeholder
Pharmacy benefit managers (PBMs) have become a rare point of bipartisan agreement in the United States. Both Republicans and Democrats are increasingly critical of these middlemen, accusing them of inflating drug costs and prioritizing corporate profits over patient care.
States like Tennessee and Arkansas are leading legislative efforts to regulate PBMs, including proposals to prevent companies from owning both insurance plans and retail pharmacies. Critics argue the current market is not truly competitive, while PBMs maintain they are essential for lowering overall healthcare costs.
In-article ad placeholder
Recommended for you
Tools and services we trust to boost productivity and content workflows.
Browse picksAd placeholder
